Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer

Authors

  • Jinming Li,

    Corresponding author
    1. National Center for Clinical Laboratory, Beijing Hospital of the Ministry of Health, Beijing, People's Republic of China
    • Correspondence to: Jinming Li, National Center for Clinical Laboratory, Beijing Hospital of the Ministry of Health, No. 1 Dahua Road, Dongdan, Beijing 100730, People's Republic of China, Tel.: +86-10-58115061, Fax: 86-10-65212064, E-mail:jmli63hn@gmail.com

    Search for more papers by this author
  • Yanli Sun,

    1. National Center for Clinical Laboratory, Beijing Hospital of the Ministry of Health, Beijing, People's Republic of China
    2. Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
    Search for more papers by this author
  • Tingting Jia,

    1. National Center for Clinical Laboratory, Beijing Hospital of the Ministry of Health, Beijing, People's Republic of China
    2. Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
    Search for more papers by this author
  • Rui Zhang,

    1. National Center for Clinical Laboratory, Beijing Hospital of the Ministry of Health, Beijing, People's Republic of China
    Search for more papers by this author
  • Kuo Zhang,

    1. National Center for Clinical Laboratory, Beijing Hospital of the Ministry of Health, Beijing, People's Republic of China
    Search for more papers by this author
  • Lunan Wang

    1. National Center for Clinical Laboratory, Beijing Hospital of the Ministry of Health, Beijing, People's Republic of China
    Search for more papers by this author

Errata

This article is corrected by:

  1. Errata: Erratum: Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer Volume 135, Issue 7, E5, Article first published online: 15 July 2014

Abstract

Prostate cancer (PCa) is the most diagnosed cancer in the western male population with high mortality. Recently, alternative approaches based on immunotherapy including mRNA vaccines for PCa have shown therapeutic promise. However, for mRNA vaccine, several disadvantages such as the instability of mRNA, the high cost of gold particles, the limited production scale for mRNA-transfected dendritic cells in vitro, limit their development. Herein, recombinant bacteriophage MS2 virus-like particles (VLPs), which based on the interaction of a 19-nucleotide RNA aptamer and the coat protein of bacteriophage MS2, successfully addressed these questions, in which target mRNA was packaged by MS2 capsid. MS2 VLP-based mRNA vaccines were easily prepared by recombinant protein technology, nontoxic and RNase-resistant. We show the packaged mRNA was translated into protein as early as 12 hr after phagocytosed by macrophages. Moreover, MS2 VLP-based mRNA vaccines induced strong humoral and cellular immune responses, especially antigen-specific cytotoxic T-lymphocyte (CTL) and balanced Th1/Th2 responses without upregulation of CD4+ regulatory T cells, and protected C57BL/6 mice against PCa completely. As a therapeutic vaccine, MS2 VLP-based mRNA vaccines delayed tumor growth. Our results provide proof of concept on the efficacy and safety of MS2 VLP-based mRNA vaccine, which provides a new delivery approach for mRNA vaccine and implies important clinical value for the prevention and therapy of PCa.

Ancillary